Develops antibody-based drug candidates for patients with severe inflammatory, allergic, autoimmune and other diseases, focusing on mast cell-driven conditions.
10-K for FY2025, filed Feb 25, 2026Celldex Therapeutics, Inc., which we refer to as “Celldex,” “we,” “us,” “our” or the “Company,” is a biopharmaceutical company dedicated to…View ↗
Barzolvolimab (also referred to as CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its…View ↗
Our next generation bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases.…View ↗
Celldex performs manufacturing, research and development services for Rockefeller University under agreements, and earns revenue under drug-development agreements with collaborative partners.
10-K for FY2025, filed Feb 25, 2026
No. It lost $258.8M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$75.6MView ↗
8-K, filed Jul 15, 2026
On July 10, 2026, Sam Martin, Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc. (the “Company”), notified the…View ↗
Therapeutic focus
The latest report centers the business description on mast cell biology and diseases mediated by mast cells; the older report also highlighted antibodies for many forms of cancer.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 25, 2026Celldex Therapeutics, Inc., which we refer to as “Celldex,” “we,” “us,” “our” or the “Company,” is a biopharmaceutical company dedicated to…View ↗
Celldex Therapeutics, Inc., which we refer to as “Celldex,” “we,” “us,” “our” or the “Company,” is a biopharmaceutical company dedicated to…View ↗
Program indications
Atopic dermatitis is in the latest report's clinical portfolio, while the older report described a planned study in eosinophilic esophagitis.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 25, 2026Eosinophilic Esophagitis (EoE): We plan to initiate a Phase 2 study in EoE in the first half of 2023.View ↗
Atopic Dermatitis (AD): A Phase 2 study in AD was initiated in December 2024 and enrollment was completed in January 2026. Topline data…View ↗
Competes with Abbvie, Akeso Bio, Amgen, Kiowa Kirin, Celltrion, Eli Lilly, Galderma, Chugai, Genentech, Novartis, Incyte, Kashiv Biosciences, Leo Pharma, Medimetriks, Pfizer, Regeneron, Sanofi, Teva, and Vanda Pharmaceuticals
10-K for FY2025, filed Feb 25, 2026AbbvieView ↗
Loading...